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viral hepatitis model and provide insights into a potential340 14
Results: Following MHV-3 infection, the number of NK
ells in livers of Balb/cJ mice increased markedly, peaked at
8 h post-infection, and remained at a high level until sac-
iﬁce. In peripheral blood, spleen, and bone marrow, this
umber decreased signiﬁcantly. Expression of CD69, cyto-
oxic activity, and intracellular IFN-/ and TNF-& production
y liver NK cells at 48 h post-infection were all signiﬁcantly
pregulated. Highly activated liver NK cells were cytotoxic
o MHV-3-infected hepatocytes and this effect was markedly
nhibited by anti-FasL plus anti-NKG2D monoclonal antibod-
es. Furthermore, the accumulation of hepatic NK cells and
ncrease in the expression of natural cytotoxicity receptors
NKP30 and NKP46) on the peripheral NK cells from patients
ith HBV-ACLF were correlated with disease progression.
Conclusion: These results indicate the pivotal involve-
ent of NK cells in the pathogenesis of FHF and HBV-ACLF,
nd the synergetic effect of Fas-FasL and NKG2D-NKG2DL
athway in liver NK cell mediation of hepatocyte toxicity.
oi:10.1016/j.ijid.2010.02.375
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MV infection causing Adult Onset Still’s Disease: A clini-
al case
. Bento1,∗, R. Leite1, R. Tavares2, A. MIranda2, F.
entura1, C. Araújo2, K. Mansinho1
West Lisbon Hospital Centre, Lisbon, Portugal
Lisbon, Portugal
Background: CMV normally causes a mononucleosis
yndrome in immunocompetent persons. Immunologic
berrations recognized with this infection include hypogam-
aglobulinemia, rheumatoid factor (RF), antinuclear anti-
odies and anticomplementary activity. CMV has been
ssociated with inﬂammatory bowel diseases, rheumatoid
rthritis, psoriasis and Wegener’s granulomatosis. Adult
nset Still’s Disease (AOSD) is an RF-negative inﬂammatory
isorder of unknown aetiology, responsible for many cases
f fever of unknown origin. It is marked by cytokine abnor-
alities and a predominant Th1-cell response.
Methods: A 34-year-old man presented himself to the
D on June 2007 with two weeks of fever, arthralgia and
ore throat. After an empirically course with Amoxicillin
lavulanate he also experienced a self-limited morbilliform
ash. On admission he exhibited 39◦ temperature, cervical
denopathies and mild splenomegaly. Analysis showed leu-
ocytosis, atypical lymphocytosis, C-RP 3.53mg/dl and ESR
1mm/h. There was an elevation of hepatic enzymes and
ositive CMV IgM and IgG. The search for Hbs, p24 antigen
nd antibodies against HIV, HCV, EBV, Toxoplasma gondii and
treptolysin-O was negative.
Results: In October 2007 he remained symptomatic. His
iver was biopsed. Histological sections in H&E identiﬁed
pithelioid granulomas, portal inﬂammation, nuclear and
ytoplasmic inclusions in hepatocytes and Kupfer cells.
mmunohistochemistry was compatible with CMV. He was
tarted on Valganciclovir. Fever remained intermittently. In
ebruary 2008 he maintained positive titers of CMV IgM and
levated liver enzymes. The search for other infections with
ultures of peripheral blood and bone marrow was negative.
ntibodies to other agents such as Brucella spp, Borrelia
pp and Coxiella burnetii were negative. Echocardiogram,
a
a
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ody CT scan and upper and lower GI endoscopy were nor-
al. Markers for autoimmune/inﬂammatory diseases such
s ANA, ANCA and RF and tumor markers were also nega-
ive. Cytometry showed an inversed TCD4+/TCD8+ ratio and
ow CD19+ B lymphocytes. IgA, IgG and IgM levels were low.
etanus vaccination resulted in antibody response, excluding
ommon Variable Immunodeﬁciency.
Conclusion: In June 2008 he maintened fever and arthral-
ia. Analysis registered leukocytosis, ESR 77mm/h and
erritin 6400 ng/ml. CMV IgM was negative and liver enzymes
ere normal. AOSD was suspected and the patient started
rednisone 1mg/kg/day. The patient had a marked improve-
ent after institution of this therapy.
oi:10.1016/j.ijid.2010.02.376
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elbivudine preserves Th1 cytokine response and down
egulates PD-L1 in MHV-3—induced viral hepatitis model
. Wu1, W. Yan1, W. Guo1, Y. Zou1, H. Wang1, X. Wang1, X.
ang1, Y. Lu1, X. Luo2, Q. Ning1,∗
Tongji Hospital, Tongji Medical College, Huazhong Univer-
ity of Science & Technology, Wuhan, Hubei, China
Tonji Hospital, Wuhan, China
Background: Telbivudine is an orally bioavailable L-
ucleoside with potent and speciﬁc anti—hepatitis B virus
HBV) activity. Recent studies have suggested a potential
mmunomodulatory effect of telbivudine. To address this,
e sought to determine the effect of telbivudine on the
mmune system, particularly cytokine production and T-cell
esponse, in the mouse hepatitis virus strain 3 (MHV-3)-
nduced hepatitis model.
Methods: The effect of telbivudine on virus replication
nd cytokines production in MHV-3 infected macrophages
ere investigated. In vivo the T cell response to Telbivudine
reatment were also studied in MHV-3 induced viral hepatitis
odel.
Results: In vitro there was no signiﬁcant difference
n MHV-3 replication in macrophages with or without tel-
ivudine treatment. The production of tumor necrosis
actor—& and interleukin-12 was increased signiﬁcantly in
HV-3—inducedmacrophages with telbivudine treatment. In
ivo survival was enhanced in telbivudine-treated mice with
arked normalization in clinical conditions and histologic
esions. Serum levels of interferon-/ were elevated signiﬁ-
antly after telbivudine treatment in MHV-3—infected C3H
ice. In contrast, serum interleukin-4 levels were decreased
igniﬁcantly. Furthermore, telbivudine treatment had a ben-
ﬁcial effect on T cells, restoring their ability to undergo
roliferation and secrete cytokines but not to enhance cyto-
oxicity on infected hepatocytes. Notably, we found that
elbivudine treatment suppressed programmed death ligand
expression on T cells.
Conclusion: These data identify an immunomodulatory
echanism of telbivudine treatment in the MHV-3—induceddditional mode of action for the management of viral hep-
titis infection.
oi:10.1016/j.ijid.2010.02.377
